PATHOQUEST
24.11.2021 13:02:07 CET | Business Wire | Press release
PathoQuest, a leading contract research organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies, today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124005881/en/
This GMP certification acknowledges PathoQuest's testing activities meet the established high-quality control standards required by the biopharmaceutical industry. Biotech and biopharma companies may now transition from early-stage projects to more advanced clinical phases and commercial batch release using the power and precision of the NGS technology. PathoQuest today offers viral safety testing services and genetic characterization of biologics.
"Obtaining the GMP certification confirms that our quality management system meets the requirements and is at the expected level by the health authorities,” stated Violaine Mélen, PharmD, PathoQuest’s Chief Quality Assurance & Regulatory Affairs Officer and Qualified Person. The GMP certification for our biosafety testing services completes our GLP certificate obtained in January 2020 and the Pharmaceutical Establishment status achieved in September 2020. Offering GMP-grade genomic testing services is our pledge of quality to the biopharmaceutical industry, the health authorities and for the safety of the patient.
“Gaining this GMP certification is a major milestone in the implementation of PathoQuest’s growth strategy and strengthens our leadership in the quality control testing of biologics,” commented Jean-Francois Brepson, PathoQuest’s CEO . "By offering these testing services we will enable our clients to entrust their vaccine, cell and gene therapy, and other innovative therapies projects to PathoQuest, from early preclinical phases to commercial supply. We believe this represents a tremendous advantage for biopharmaceutical companies when they evaluate contract manufacturing alternatives that are faster, safer and 3R-compliant at a Good Manufacturing Practice grade. Those assets make PathoQuest the ideal partner.”
PathoQuest’s GMP certificate is available for our clients to download from our website along with the company’s current GLP certificate and the notice of achieving Pharmaceutical Establishment status.
About PathoQuest
PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, GLP and GMP grades to ensuring the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.
For more information, visit www.pathoquest.com or contact us at welcome@pathoquest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kingswood Capital Management Enters Into a Definitive Agreement to Acquire Coveris’ Paper Unit, Rebrands as Paragon Print and Packaging10.2.2026 13:00:00 CET | Press release
Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) announced today that it has entered into a definitive agreement to acquire Business Unit Paper (“BU Paper”) from Coveris, a global manufacturer of paper and plastic packaging solutions. As part of the transaction, BU Paper will be rebranded Paragon Print and Packaging (“Paragon”), restoring the unit’s original name. Jo Ormrod, Chief Operating Officer, will serve as Paragon’s Chief Executive Officer, and the existing company management will remain in place. The transaction is expected to close in several weeks, subject to customary legal and regulatory requirements. Paragon produces high-quality, sustainable paper-based packaging solutions, including for key end markets such as food, household, and personal care. The company, which was established in 1994, specializes in products like self-adhesive and linerless labels, lined board, cartons, and trays using eco-friendly materials. “We are excited about our next
Umm Al Qura for Development & Construction Company Concludes Participation in Real Estate Future Forum 202610.2.2026 12:59:00 CET | Press release
Participation coincides with Masar Destination receiving LEED Gold certification Umm Al Qura for Development & Construction Company, the owner, developer, and operator of Masar Destination in Makkah, has concluded its participation as a strategic partner in this year’s Real Estate Forum (RFF). The forum was held in Riyadh from January 26 to 28 under the patronage of His Excellency, the Minister of Municipal Rural Affairs and Housing, Mr. Majid bin Abdullah Al-Hogail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210508479/en/ Masar Promenade View (Photo: AETOSWire) The company’s pavilion, which drew strong interest from investors and visitors, presented Masar Destination’s key components, available investment opportunities, and recent project developments. It also highlighted the significant progress achieved in recent months. During the forum, Umm Al Qura for Development & Construction announced the launch of a unified
Ireland Takes Centre Stage as MICHELIN Awards Come to Dublin for the First Time10.2.2026 12:06:00 CET | Press release
Ireland’s reputation as a world-class culinary destination was celebrated this evening as the MICHELIN Guide UK & Ireland Awards were held in Ireland for the very first time, celebrating the country’s exceptional chefs, restaurants and producers on an international stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209670808/en/ Fôret Restaurant, Dublin At a ceremony hosted in Dublin, MICHELIN unveiled its latest selection for the UK & Ireland, with a number of Irish restaurants recognised for their creativity, craftsmanship and commitment to quality, marking a significant moment for Ireland’s evolving food scene and its growing appeal among international diners. The ceremony included the announcement of the MICHELIN Stars, the Bib Gourmands for great value dining, and a series of Special Awards recognising outstanding individuals and teams in hospitality. Eight Irish restaurants were awarded in total at the ceremony.
MultiBank Group Launches 50% Rebate Boost for IBs & 25% Deposit Bonus for Clients10.2.2026 11:43:00 CET | Press release
MultiBank Group, one of the world’s largest and most regulated financial derivatives institution, has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210880239/en/ MultiBank Group has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. The programs reflect the firm's ongoing strategy to strengthen relationships across its partner and client ecosystem while maintaining the competitive positioning that has supported the Group's growth since its establishment in 2005. Elite IB Promo: Enhanced Partner Compensation Under the Elite IB Promotion, MultiBank Group's Introducing Brokers are eligible to receive a 50% boost on their standard rebate and commission structures. The program provides IBs t
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom